Cefdinir intermediate
    18.
    发明授权
    Cefdinir intermediate 有权
    头孢地尼中间体

    公开(公告)号:US07825241B2

    公开(公告)日:2010-11-02

    申请号:US11766132

    申请日:2007-06-21

    IPC分类号: C07D501/22

    CPC分类号: C07D501/00

    摘要: 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid of formula (I), in the form of a crystalline salt and use thereof, e.g. in the preparation of pure cefdinir. In another aspect this invention relates to the compound of formula (I) in the form of a salt, optionally in crystalline form, wherein the salt is selected from the group consisting of phosphate, hydrogen phosphate, mesylate, tosylate, sulfate, hydrogen sulfate and sulfamate.

    摘要翻译: 以式(I)表示的7- [2-(2-氨基噻唑-4-基)-2-(甲基羰氧基亚氨基)乙酰氨基] -3-乙烯基头孢烯-4-羧酸的结晶盐及其用途, 例如 在制备纯头孢地尼。 另一方面,本发明涉及任选呈结晶形式的盐形式的式(I)化合物,其中所述盐选自磷酸盐,磷酸氢盐,甲磺酸盐,甲苯磺酸盐,硫酸盐,硫酸氢盐和 氨基磺酸盐。

    Cefdinir intermediate
    19.
    发明申请
    Cefdinir intermediate 失效
    头孢地尼中间体

    公开(公告)号:US20060025586A1

    公开(公告)日:2006-02-02

    申请号:US10524397

    申请日:2003-08-12

    IPC分类号: C07D501/14

    CPC分类号: C07D501/00

    摘要: 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid of formula I in the form of a crystalline salt and use thereof, e.g. in the preparation of pure cefdinir. In another aspect this invention relates to the compound of formula I in the form of a salt, optionally in crystalline form, wherein the salt is selected from the group consisting of phosphate, hydrogen phosphate, mesylate, tosylate, sulfate, hydrogen sulfate and sulfamate.

    摘要翻译: 具有结晶盐形式的式I的7- [2-(2-氨基噻唑-4-基)-2-(甲基羰氧基亚氨基)乙酰氨基] -3-乙烯基头孢烯-4-羧酸及其用途, 在制备纯头孢地尼。 在另一方面,本发明涉及任选呈结晶形式的盐形式的式I化合物,其中盐选自磷酸盐,磷酸氢盐,甲磺酸盐,甲苯磺酸盐,硫酸盐,硫酸氢盐和氨基磺酸盐。